# Mepolizumab in Nasal Polyposis

> **NCT01362244** · PHASE2 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 109 (actual)

## Conditions studied

- Nasal Polyps

## Interventions

- **DRUG:** Mepolizumab
- **DRUG:** Placebo
- **DRUG:** Run In Medication

## Key facts

- **NCT ID:** NCT01362244
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-05-12
- **Primary completion:** 2014-12-05
- **Final completion:** 2014-12-05
- **Target enrollment:** 109 (ACTUAL)
- **Last updated:** 2021-04-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01362244

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01362244, "Mepolizumab in Nasal Polyposis". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01362244. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*